EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study

Oluseyi Ayinde iD, Jonathan D C Ross, Louise Jackson

PLOS ONE · 19.10.2023 · 18 (10) · e0292273

DOI: 10.1371/journal.pone.0292273 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 19.10.2023. Verfasst von Oluseyi Ayinde und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sexual Health and HIV, University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom. Hauptthemen laut MEDLINE: Gonorrhea, Sexually Transmitted Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To provide a summary of the economic and methodological evidence on capturing antimicrobial resistance (AMR) associated costs for curable sexually transmitted infections (STIs). To explore approaches for incorporating the cost of AMR within an economic model evaluating different treatment strategies for gonorrhoea, as a case study.

Methods

A systematic review protocol was registered on PROSPERO (CRD42022298232). MEDLINE, EMBASE, CINAHL, Cochrane Library, International Health Technology Assessment Database, National Health Service Economic Evaluation Database, and EconLit databases were searched up to August 2022. Included studies were analysed, quality assessed and findings synthesised narratively. Additionally, an economic evaluation which incorporated AMR was undertaken using a decision tree model and primary data from a randomised clinical trial comparing gentamicin therapy with standard treatment (ceftriaxone). AMR was incorporated into the evaluation using three approaches—integrating the additional costs of treating resistant infections, conducting a threshold analysis, and accounting for the societal cost of resistance for the antibiotic consumed.

Results

Twelve studies were included in the systematic review with the majority focussed on AMR in gonorrhoea. The cost of ceftriaxone resistant gonorrhoea and the cost of ceftriaxone sparing strategies were significant and related to the direct medical costs from persistent gonorrhoea infections, sequelae of untreated infections, gonorrhoea attributable-HIV transmission and AMR testing. However, AMR definition, the collection and incorporation of AMR associated costs, and the perspectives adopted were inconsistent or limited. Using the review findings, different approaches were explored for incorporating AMR into an economic evaluation comparing gentamicin to ceftriaxone for gonorrhoea treatment. Although the initial analysis showed that ceftriaxone was the cheaper treatment, gentamicin became cost-neutral if the clinical efficacy of ceftriaxone reduced from 98% to 92%. By incorporating societal costs of antibiotic use, gentamicin became cost-neutral if the cost of ceftriaxone treatment increased from £4.60 to £8.44 per patient.

Conclusions

Inclusion of AMR into economic evaluations may substantially influence estimates of cost-effectiveness and affect subsequent treatment recommendations for gonorrhoea and other STIs. However, robust data on the cost of AMR and a standardised approach for conducting economic evaluations for STI treatment which incorporate AMR are lacking, and requires further developmental research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GonorrheaSexually Transmitted DiseasesHumansAnti-Bacterial AgentsCeftriaxoneCost-Benefit AnalysisDrug Resistance, BacterialGentamicinsState Medicine

Substanzen

Anti-Bacterial AgentsCeftriaxoneGentamicins

Autor:innen und Institutionen

  • Sexual Health and HIV, University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom.
  • Health Economics Unit, Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom.

ORCID-Profile: Oluseyi Ayinde

Zitieren

APA

Ayinde, O., Ross, J. D. C., & Jackson, L. (2023). Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study. PLOS ONE, 18(10), e0292273. https://doi.org/10.1371/journal.pone.0292273

Vancouver

Ayinde O, Ross JDC, Jackson L. Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study. PLOS ONE. 2023;18(10):e0292273. doi:10.1371/journal.pone.0292273

BibTeX
@article{Ayinde2023,
  author = {Ayinde, Oluseyi and Ross, Jonathan D C and Jackson, Louise},
  title = {Economic evaluation of antimicrobial resistance in curable sexually transmitted infections; a systematic review and a case study},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {10},
  pages = {e0292273},
  doi = {10.1371/journal.pone.0292273}
}
Kostenlos starten →